The Big 4 Orthos sold $15B of total joint implants last year... so why aren't the Big 4 Orthos focused on preventing revisions ?
I understand that revisions will always happen because of infections, loosening, continued pain, bad surgeries, dislocation.... but 15% is unacceptable.
The Big 4 are always working on the next implant thingy or the next surgical approach or a robot. Its like they consider the total joint industry as a "feature industry" or worse, a "fashion industry", not a "let's improve clinical outcomes" industry.
Why don't they focus on minimizing the 15% revision rate each year ?
What am I missing here ?
In a article in BareBones titled, Joint Replacement Leaders Focus on Implant Improvements, Carolyn LaWell wrote that in 2023, Zimmer Biomet, Stryker, DePuy Synthes, and Smith+Nephew dominated nearly 70% of the global joint replacement market, which grew by 7.5% to $21.5 billion. These leading companies anticipate continued strong performance in 2024, driven by increased demand for procedures and the adoption of new implants and enabling technologies. Zimmer Biomet is set to launch the stemless Identity Shoulder System to cater to active patients, while S...
